Inside Eli Lilly's GLP-1 Empire: The Most Important Drug Franchise in a Generation

To understand Lilly's position, you need to understand the competitive dynamics. The GLP-1 market is effectively a duopoly between Lilly and Novo Nordisk, with Lilly's tirzepatide (the molecule behind both Mounjaro and Zepbound) demonstrating superior weight loss efficacy in head-to-head trials. That efficacy advantage matters — it drives physician preference, patient demand, and pricing power.

The obesity indication is where the real growth lives. Zepbound launched in late 2023 and is already generating billions in quarterly revenue despite persistent supply constraints. Lilly has been investing heavily in manufacturing capacity — the company spent over $18 billion on capex in 2025 alone — and the supply bottleneck is expected to ease through the second half of 2026. When it does, the revenue inflection could be dramatic.

Amazon's advertising business followed a similar trajectory as AWS in 2015-2018, quietly becoming the profit engine while the market obsessed over another segment. Lilly's obesity franchise is doing the same thing relative to its diabetes base — it's becoming the growth driver that renders the rest of the portfolio secondary.

Lilly's current profitability metrics look underwhelming relative to the revenue growth — net income was $4.4 billion on $45 billion in revenue in 2025, implying a net margin of about 10%. That's well below pharma peers. But the margin profile is distorted by two factors that are both temporary.

First, the massive manufacturing buildout is hitting the P&L through accelerated depreciation and ramp-up costs. Lilly is building capacity for a product that hasn't reached peak demand yet — the capex is frontloaded, the revenue is backloaded. Second, the company is spending aggressively on clinical trials for next-generation GLP-1 compounds, including an oral formulation that could dramatically expand the addressable market.

As manufacturing utilisation improves and clinical trial spending normalises, we expect operating margins to expand from the current 22% toward 30-35% over the next three to four years. That's not a heroic assumption — it's roughly where Novo Nordisk's GLP-1 margins sit today, and Lilly has a superior efficacy profile.

The market is rightly focused on the GLP-1 franchise, but Lilly's pipeline extends well beyond metabolic disease. The company has late-stage assets in Alzheimer's (donanemab), immunology, and oncology. Donanemab alone could be a $5-10 billion peak revenue product if the Alzheimer's market develops as neurologists expect.

The pipeline provides a hedge against the bull case's biggest vulnerability: what happens when GLP-1 competition intensifies. Amgen, Pfizer, and Viking Therapeutics all have GLP-1 programmes in clinical development. By 2028-2029, the duopoly will likely become an oligopoly. Lilly needs its pipeline to deliver the next growth driver before that competitive pressure arrives.

The consensus has been wrong before on this name — we were too cautious on the obesity launch timeline in 2023. The data hasn't made us more cautious.

At 67x trailing earnings, Lilly is expensive by any traditional pharmaceutical metric. The forward PE of 35x is more palatable but still premium. The question is whether the growth rate justifies the multiple — and the honest answer is that it depends entirely on the obesity market's size and Lilly's share of it.

Bull case: the obesity market reaches $150 billion globally by 2030, Lilly captures 45-50% share, margins expand to 35%, and the stock is worth $1,200+ per share. Bear case: competitive pressure caps margins at 25%, market growth disappoints, and the stock is worth $600-700. The current price of around $830 sits right in the middle of that range.

The analyst consensus target of $1,067 implies 28% upside — aggressive but not unreasonable if the manufacturing ramp proceeds on schedule. The 17 Buy ratings versus 3 Holds and zero Sells tell you where institutional conviction sits.